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Background: Obesity and major depressive disorder (MDD) are important public health problems. MDD is a
heterogeneous disorder and the direction of its association with obesity remains unclear. Evidence grows that
recurrent MDD (MDD-R) differs in etiology and prognosis from single episode MDD (MDD-S), which could affect
associations with obesity. However, evidence on this differential effect is lacking. The aim of this study was to
examine the direction of the association between obesity and MDD, single or recurrent episode.
Methods: A longitudinal study was performed in a cohort of 1094 participants of the PREVEND study, on whom
data were collected at baseline and at an average 2-year follow-up. MDD-S and MDD-R were assessed by the
Composite International Diagnostic Interview (CIDI 2.1). Obesity was defined as Body Mass Index ≥ 30 kg/m2. Binary
logistic regression analyses were conducted to examine whether obesity predicts MDD-S/MDD-R or vice versa,
adjusted for potential confounders.
Results: Prospective analyses showed that BMI at baseline was associated with the onset of MDD-R (Odds ratio,
OR = 1.32; 95% confidence interval, 95%CI: 1.11; 1.57) during 2-year follow-up, but not with the onset of MDD-S
(OR = 0.98; 95%CI: 0.89; 1.07). Obesity at baseline was not associated with the onset of MDD-S during follow-up
(OR = 0.75; 95%CI: 0.25; 2.30), but associated with the onset of MDD-R during follow-up (OR = 11.63; 95%CI: 1.05;
128.60). Neither MDD-S nor MDD-R were associated with the development of obesity during 2-year follow-up
(OR = 1.67, 95%CI: 0.64; 4.29 and OR = 2.32, 95%CI: 0.82; 6.58, respectively).
Conclusions: Our findings add to the available evidence that obesity might specifically be associated with the
onset of multiple episodes of major depression (MDD-R). Although the reverse association was not found, MDD-R
tends to be also associated with subsequent development of obesity, but larger studies are needed to fully assess
this issue. The heterogeneity of MDD should be considered when examining the effect of obesity on MDD.
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Obesity and major depressive disorder (MDD) have been
recognized as major public health problems [1,2]. Both
obesity and MDD increase the risk of adverse health
outcomes, such as diabetes II, cardiovascular diseases
and premature death [3]. Notably, depression is expected
to rank first in disease burden in developed countries by
2030 [2].The lifetime incidence of major depression is* Correspondence: y.t.nigatu@umcg.nl
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unless otherwise stated.about 16% in the US general population [4]. Further-
more, antidepressant medication (ADM) is currently one
of the most commonly prescribed classes of medication
in outpatient medical practices in the US [5]. The preva-
lence of obesity has tripled concurrently with the rate of
depression in many countries of the World Health
Organization (WHO) European Region since the 1980s,
and continues to rise at an alarming rate [1,6].
Obesity and depression often co-occur in cross-
sectional studies [7-12]. To date, the direction of the
association between obesity and depression is not
clearly established, though a meta-analysis and severalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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meta-analysis suggested a bidirectional association
between obesity and depression even though only 8
studies were included [16]. In addition, a systematic
review of primarily cross-sectional studies showed a
weak association between obesity and depression [18].
Two longitudinal studies suggested that obesity was
associated with depression at 1 and 5-year follow-up
[17,19]; one also assessed whether depression predicted
obesity, but did not find such an association [19]. A recent
prospective study among 65,595 female nurses in the US
showed bidirectional associations between obesity and
depression [20]. It is questionable, however, whether these
findings can be generalized to the general population.
Finally, a Canadian study suggested that obesity had a
protective effect against depression during 12-year
follow-up [14].
Overall, the direction of the association between obes-
ity and depression remains unclear. The inconclusive
results could stem from the use of different methods to
assess depression and most of the studies used self-
reported measures [9-11,14,17,19-21]. Self-reported
measures will increase measurement error and could
introduce information bias. The use of inadequate time
frames for measuring depression could be another rea-
son [14]. For instance, the Alameda County study in
the US and the Canadian study [14,17,19], used past
month or past two weeks’ time frames, which could
classify individuals with past year or lifetime depres-
sion as non-depressed. This could lead to an underesti-
mation of the association between depression and
obesity. Furthermore, differences in the study setting
could have contributed to the inconsistencies in find-
ings. For instance, the association between obesity and
depression was more marked in US than European
populations [10,16,22].
To our knowledge, no study has yet investigated the
associations between obesity and major depressive dis-
order single (MDD-S) versus recurrent episode (MDD-
R). The distinction may be important because one of the
challenges in understanding depression is the heterogen-
eity of the disorder [21], with growing evidence that
MDD-R differs in etiology and prognosis from MDD-S
[23-28]. MDD-R patients have been shown to have lon-
ger durations of episodes, more somatic symptoms and
poor responses to treatment relative to MDD-S patients
[23-28]. In addition, new episodes of major depression
(MDD-S) are often triggered by stressful life events,
whereas MDD-R seems to be mostly due to stable risk
factors (i.e., obesity) [23-28]. Moreover, MDD-R patients
have been shown to have a chronic exposure to an un-
healthy life style and psychological problems including
emotional eating compared to MDD-S [27]. Chronic ex-
posure to these life events may result in fluctuation andstronger neural or endocrine responses, which may
cause an increase in appetite, hypersomnia and lack of
coping [27,28]. The physiological mechanism that could
link MDD-R and obesity is the repeated activation of
hypothalamic pituitary adrenal (HPA) axis [29,30]. This
chronic activation of the HPA axis is associated with in-
flammation and glucocorticoid signaling, where the glu-
cocorticoids have been shown to promote deposition of
fat by impairing the insulin activity [31]. Glucocorticoids
are also involved in promoting the differentiation and
proliferation of human adipocytes and have been shown
to be positively associated with all indices of obesity
such as elevated body mass index and an increased
abdominal fat [29-31]. Therefore, these mechanisms sug-
gest that MDD subtypes could have a different effect on
obesity; but to date, evidence supporting this differential
effect is lacking.
The aim of this study was therefore to examine
whether obesity was a risk factor for the onset of either
MDD-S or MDD-R and vice versa. The study was per-
formed in a longitudinal general population cohort.
Methods
Study population and procedure
The study was performed in a cohort derived from the
longitudinal PREVEND (Prevention of REnal and Vascular
ENd stage Diseases) study, a Dutch population-based co-
hort study at the University Medical Center Groningen
that investigates risk factors for renal and cardiovascular
disease [32]. In 1997, all the inhabitants of the city of
Groningen aged between 28 and 75 years (N = 85,421
subjects) were asked to send a morning urine sample and
a demographic history. A total of 40,856 subjects (47.8%)
responded. After exclusion of subjects with insulin
dependent diabetes mellitus and pregnant women, all
subjects with an elevated urinary albumin concentra-
tion of > =10 mg/l (N = 7768) along with a randomly
selected control group with a urinary albumin concen-
tration of <10 mg/l (N = 3395) were invited for further
investigation (total N = 11,163). Finally, 8592 subjects
completed the whole screening programme, forming
the PREVEND baseline sample [32].
The selection of subjects for the present study was
aimed at recruiting a representative sample of the general
population of Groningen, while simultaneously rectifying
PREVEND’s oversampling for albuminuria. Albuminuria
negative participants were combined with a random sam-
ple of albuminuria positive participants until a population
representative ratio was achieved. Research assistants
approached 2554 PREVEND participants during their visit
to the out-patient clinic during follow-up. Questionnaires
were completed by a total of 1094 PREVEND participants.
There were no significant differences in age and gender
between PREVEND participants who agreed or refused to
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minimum sample size required a priori for both depres-
sion and obesity as an outcome, using assumptions that
have been derived from the results of the US Alameda
County study [17]. We took the incidence of depression in
the obese group (p1) as 13.5%, and in the non-obese group
(p2) as 7%, and set the probability of a type I error (α) and
a type II error (β) as 0.05 and 0.2, respectively. The total
sample size required for this was N = 682 subjects. For
obesity, we took the incidence of obesity in depressed
group (p1) as 31.2%, and in the non-depressed group (p2)
as 19.1% based on the results of the Alameda County
Study [17], and set the probability of a type I error (α) and
a type II error (β) as 0.05 and 0.2, respectively. The total
sample size required for this was N = 402 subjects.
The baseline measurement for the present study among
1094 PREVEND participants took place in 2002/ 2003, the
follow-up measurement between 2004 and 2006, and were
completed by a total of 964 participants (88%). The study
was approved by the Medical Ethics Committee of the
University Medical Center Groningen and was conducted
in accordance with the guidelines of the Declaration of




Body mass index (BMI) at baseline and follow-up was
derived from the information collected on height and
weight. After removal of shoes and heavy clothing,
weight was measured to the nearest 0.5 kg using a single
scale. Height was measured to the nearest 0.5 cm. The
Body Mass Index (BMI) was calculated as weight (kg)
divided by height (metres) square. In the analyses, BMI
was used both as a continuous variable and as a dichot-
omized variable. BMI was dichotomized based on
World Health Organization (WHO) criteria as <30 kg/m2
(non-obese) and ≥30 kg/m2 (obese) [1]. We took a 2 year
period between measurements as this is the average time
period needed to detect MDD-R and to detect clinically
relevant changes in BMI [20].
Major Depressive Disorder (MDD)
MDD was assessed by the Composite International
Diagnostic Interview (CIDI 2.1). The CIDI is a struc-
tured clinical interview and diagnoses according to
definitions and criteria of the fourth edition of the
American Psychiatric Association’s Diagnostic and Stat-
istical Manual of Mental Disorders (DSM-IV). The CIDI
contains questions directly corresponding to the symp-
toms of axis I psychiatric disorders listed in the DSM-
IV. It translates the criteria of DSM-IV into questions
that could be readily and reliably answered by the gen-
eral population. For example, ‘In the past 12 months,have you had two weeks or longer when nearly every
day you felt sad or depressed for most of the day?’, and
‘In the past 12 months, have you had two weeks or lon-
ger when you lost interest in most things like work or
social activities you usually enjoyed?’ The participant
was asked to answer the questions with yes or no. The
questions each describe a criterion for a diagnosis to be
made. Responses to these questions are put together by
computer algorithms ─ first to assess each criterion, and
then to combine criteria into diagnoses.
At baseline, participants first completed the CIDI
lifetime version to assess if a respondent sufficed the
criteria for a lifetime MDD diagnosis. At 2-year follow-
up, participants were interviewed and completed the
12-month CIDI version. We also used the lifetime
interview information collected at baseline to make a
diagnosis of depressive episodes in the past 12 months,
and to determine whether such an episode during the
preceding 12 months was a first episode or a recurrent
episode, depending on the outcomes of the lifetime
part of the baseline interview. We did the latter be-
cause the respondents sometimes forget their previous
episode and report as a new episode. In the CIDI 12-
months version, age of onset or recency (time since last
depressive episode or being in remission) was recorded,
which helps to assess episode changes during follow-up.
The participants were asked to indicate the recency or re-
mission: less than a month ago, between one and 6 months
ago, between 6 and 12 months ago and over 12 months
ago retrospectively. The interview was conducted by
CIDI- trained interviewers (e.g. graduate students, clini-
cians, postdocs etc.) under the supervision of clinicians.
All interviews were recorded to enable periodic checks on
consistency and quality.
MDD-S was defined, following the DSM-IV, as the
presence of a single major depressive episode, which was
characterized by the presence of five or more symptoms
during a 2-weeks’ period and by symptoms causing
problems in social interactions, work and functioning; at
least one of the symptoms is either feelings of sadness or
lack of interest or pleasure for most of the day or nearly
every day, along with other symptoms such as poor ap-
petite, difficulty sleeping, feelings of worthlessness or
guilt, decreased energy, and thoughts of death. These
symptoms, however, should not be due to the direct
physiological effects of a substance or general medical
condition; or else accounted by bereavement to be diag-
nosed as major depressive episode.
MDD-R was defined, following the DSM IV, as the
presence of two or more major depressive episodes
within 2 years [33]. To be considered as separate epi-
sodes, there must be an interval between episodes of at
least two consecutive months in which the criteria for a
major depressive episode are not met. A new diagnosis
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the findings from the CIDI lifetime interview with those
of the 12-months version. To confer major depressive
disorder as the most likely diagnosis, other potential
diagnoses were excluded, including dysthymia, which is
a milder mood disturbance in which a person reports a
low mood almost daily over a span of at least two years
and additional symptoms such as hopelessness and loss
of self-esteem. To be considered dysthymia, the depres-
sive episodes must not have occurred in the first 2 years
(DSM-IV).
Potential confounders
Demographic factors such as age, sex, marital status,
level of education, frequency of exercise per week and
smoking were included as confounders because these
were reported to have an association with both obesity
and major depression [3,7,14,16,20,34,35]. Age (measured
in years), sex, marital status (never married/widowed/
divorced/separated and married/living together), level
of education (high, middle, low level and not applic-
able), frequency of exercise (do not exercise/hardly per
week, once per week and twice or more per week), and
smoking status (yes or no) were assessed at baseline.
Statistical analyses
First, we described the characteristics of the cohort
using means, proportions and standard deviations. Sec-
ond, we assessed the association between baseline sam-
ple characteristics and sex. Differences in means and
proportions were tested by Student’s t-tests and chi-
square tests, respectively.
Third, binary logistic regression analyses were used to
examine the association of baseline obesity with the
diagnosis of MDD-S during follow-up, participants who
had a prior history of MDD at baseline were excluded.
Then, to examine the association between obesity and a
new diagnosis of MDD-R at follow-up, we excluded par-
ticipants who had a lifetime MDD diagnosis at baseline
because we were interested in new cases of MDD-R and
because the lifetime history of a major depressive epi-
sode is a well-known risk factor for persistence of MDD
[27]. There were no differences in sociodemographic
characteristics (i.e. sex, income, and education) and BMI
(mean BMI =26.1 vs. 26.5, P > 0.05) between included
and excluded individuals. Fourth, to assess the associ-
ation of MDD-S/MDD-R with the subsequent develop-
ment of obesity, we used binary logistic regression
analysis. Participants who were obese at baseline were
excluded from analyses [19]. There were no significant
differences in sociodemographic characteristics and in
lifetime prevalences of MDD between included and ex-
cluded individuals. To assess the effect of body weight
across its entire range on MDD-S/MDD-R and viceversa, we repeated the analyses with BMI as a continu-
ous variable.
All analyses were adjusted for age, sex, marital status,
level of education, frequency of exercise and smoking.
Interactions between the main exposures and sex were
checked by entering their interaction terms to the
models for each outcome. We also checked any potential
relationship between BMI and MDD by including BMI
and BMI-squared in the models. Crude odds ratios
(OR), adjusted odds ratios (aOR) and regression coeffi-
cients (B) were presented with 95% confidence intervals
(95%CI) for all analyses. All p values less than 0.05 were
considered statistically significant. Analyses were per-
formed using the Statistical Package for Social Sciences
version 20.0 (SPSS Inc., Chicago, IL, US).
Results
Baseline characteristics
The study population consisted of 1094 subjects aged 33
to 79 years. The mean age of the participants was 53.1
(SD = 11.4) years. At baseline, the lifetime prevalence for
MDD-S and MDD-R was 13% and 8%, respectively. The
prevalence of obesity at baseline was 17% (Table 1). The
prevalence of MDD-S and MDD-R among obese individ-
uals was 9% and 10%, respectively. The prevalence of
MDD-S and MDD-R among non-obese individuals was
13% and 8%, respectively.
As shown in Table 1, the prevalence of MDD-S was
10% in males and 15% in females (χ2, p <0.02). The
prevalence of MDD-R among males was 5% and 11% in
females (χ2, p < 0.001). No difference was found in the
prevalence of obesity in male (15%) versus female (18%)
participants (χ2, p < 0.17).
BMI/Obesity as a risk factor for MDD-S/MDD-R
The mean follow-up time was 2.17 (SD = 0.48) years.
The incidence rates of MDD-S and MDD-R were
24.5 and 1.9 per 1000 person-years, respectively. As
shown in Table 2, BMI at baseline was not associated
with the onset of MDD-S during follow-up (OR = 0.98;
95%CI: 0.89; 1.07), but associated with the onset of
MDD-R during follow-up (OR = 1.32; 95%CI: 1.11; 1.57)
(Table 2). Obesity (BMI ≥ 30) at baseline was also not
associated with the onset of MDD-S during follow-up
(OR = 0.75; 95%CI: 0.25; 2.30), but associated with the
onset of MDD-R during follow-up (OR = 11.63; 95%CI:
1.05; 128.60) (Table 2). We found no significant inter-
action between sex and the determinants, and no sig-
nificant U- or otherwise shaped relationship between
BMI and MDD.
MDD-S/MDD-R as a risk factor for BMI/Obesity
The incidence of obesity was 19.8 per 1000 person-years
during an average 2-year follow-up.
Table 1 Baseline sample characteristics by sex
N = 1094 Total Males (n = 506) Females (n = 588) χ2
Age, mean (SD) 53.1(11.4) 53.8(11.6) 52.5(11.1)
Marital status (% married /living together) 54.6 61.1 49.0 p < 0.05
Level of education (%)
High 41.7 41.1 41.9 p >0.05
Middle 27.1 28.4 26.0
Low 26.5 25.2 27.5
Not applicable 4.7 5.0 4.6
Frequency of exercise
Do not exercise/hardly 10.6 12.7 8.7 p >0.05
Once per week 10.2 10.3 10.1
Twice or more per week 79.2 76.9 81.2
Smoking (%)
No 76.1 74.4 77.5 p >0.05
Yes 23.9 25.6 22.5
Obesity (BMI≥ 30 kg/m2) (%) 16.9 15.2 18.4 p >0.05
MDD-S# (%) 12.5 10.0 14.7 p < 0.05
MDD-R# (%) 8.2 5.4 10.6 p < 0.05
MDD-S/MDD-R, major depressive disorder- single/recurrent episode - Statistically significant if p < 0.05; #16 (1.5%) individuals had no information available on
MDD-S/MDD-R at baseline; SD: Standard deviation.
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MDD-R and the subsequent increase of BMI during
2-year follow-up (B = −0.37, 95%CI: −1.19; 0.44 and B =
0.45, 95%CI: −0.51; 1.41, respectively). There was also no
significant association between MDD-S/MDD-R and the
subsequent development of obesity during 2-year follow-
up (OR = 1.67, 95%CI: 0.64; 4.29 and OR = 2.32, 95%CI:
0.82; 6.58, respectively) (Table 3). We found no significant
interaction between sex and the determinants. Further-
more, at baseline, 8% and 17% of individuals had increased
appetite and decreased appetite problems during their de-
pressive period, respectively. An increased appetite during
a depressive period was associated with the incidence of
obesity during a 2-year follow-up (OR = 1.93, 95%CI: 1.14;Table 2 Baseline BMI/obesity and rate of MDD-S/MDD-R at fo
Parameter Major depressive
MDD-S OR (95%CI
Body Mass Index (BMI)
Crude model 0.97 (0.88; 1.07)
Adjusted Modelc 0.98 (0.89; 1.07)
Obesity (BMI ≥ 30 kg/m2)
Non obese Ref.
Obese (Crude) 0.75 (0.26; 2.20)
Obese (adjusted)c 0.75 (0.25; 2.30)
OR: odds ratio; CI: confidence interval; OR of BMI represent the effect of an increase
episode; aDuring prospective analyses, 192/964 (20%) individuals with a lifetime dia
with MDD-R at baseline were excluded during analysis. cAdjusted for age, sex, mari3.24), but after adjustment for baseline obesity, this associ-
ation became non-significant (OR = 1.24; 0.49; 3.11).
Discussion
This longitudinal study showed that obesity was associ-
ated with the onset of MDD-R but not MDD-S at 2-year
follow-up. With regard to the reverse association, neither
MDD-S nor MDD-R was associated with the subsequent
development of obesity during 2-year follow-up.
Our finding that obesity was associated with the onset
of MDD-R but not of MDD-S is in line with the findings
of a recent meta-analysis [16], the Alameda study in the
US [17,19] and the US nurse study [20], all of which
found that baseline obesity had an increased odds ofllow-up (N = 964)
disorder (MDD)






of ‘1’ of the BMI; ; MDD-S/MDD-R, major depressive disorder- single/recurrent
gnosis of MDD-S/MDD-R at baseline were excluded; b78/964 (8%) individuals
tal status, education, exercise and smoking status.
Table 3 Baseline MDD-S/MDD-R/Dysthymia and onset of obesity during follow-up (N = 964)
Parameter Body Mass Index (BMI) Obesity (N = 849)b
B (95% CI) Ba (95% CI) OR (95%CI) aORa (95%CI)
No MDD-S Ref. Ref. Ref. Ref.
MDD-S −0.51 (−1.27; 0.25) −0.37 (−1.19; 0.44) 1.83 (0.78; 4.32) 1.67 (0.64,4.29)
No MDD-R Ref. Ref. Ref. Ref.
MDD-R 0.22 (−0.70; 1.13) 0.45 (−0.51; 1.41) 2.19 (0.82; 5.87) 2.32 (0.82,6.58)
B: regression coefficient; aOR: adjusted odds ratios; aadjusted for age, sex, marital status, education, exercise and smoking; b115/964 (12%) obese individuals at
baseline were excluded during prospective analysis; MDD-S/MDD-R, major depressive disorder- single/recurrent episode.
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MDD subtypes. The present study suggests that this
association was particularly due to one subtype of MDD,
which could also explain some of the heterogeneity in
findings to date. Our findings contrast with those of a
Canadian study [14], which revealed that obesity was not
associated with the onset of major depression during
12-year follow-up in women, but negatively (protective)
associated with major depression in men. This discrep-
ancy could result from the methodological differences
between the Canadian study and our study. The shorter
time frame (i.e. the past 2 weeks and 2 months) and the
method of diagnosing depression in the Canadian study
could explain why it did not show an association be-
tween obesity and subsequent development of major
depression.
We found no association of MDD-S or MDD-R with
subsequent development of obesity. This finding is in
accordance with the Alameda county study in the US,
which revealed that depression at baseline was not asso-
ciated with an increased risk of obesity during 5-year
follow-up [17]. In contrast, our finding was not in line
with earlier studies performed by Pan et al. and Luppinno
et al., which reported that depression at baseline was sig-
nificantly associated with future obesity during follow-up
[16,20]. The study by Pan et al. was based on 65,955 US
female nurses and measured depression as medication use
and physician-diagnoses [16], which raise questions re-
garding generalizability and validity [36]. In contrast, we
had a full general population sample and used standar-
dised psychiatric interviews.
Overall, obesity was associated with experiencing one
or more episodes of depression (MDD-R), but not with a
single episode (MDD-S). An explanation for the associ-
ation of obesity specifically with MDD-R could be re-
lated to structural changes in the brain that occurred
among obese and recurrently depressed people, particu-
larly in the hippocampus where emotions are regulated
[37-39]. Lower hippocampus volume and obesity have
been found to co-occur in middle-aged adults [37],
perhaps obesity as a low grade inflammatory state results
in a decreased microstructural integrity in the brain
[31,40]. These structural deformities, specifically lowerhippocampal volume, have been observed in individuals
with MDD-R as compared to individuals with MDD-S in
a single study that systematically compared first episode
and recurrently depressed patients [39]. Therefore, the as-
sociation between obesity and MDD-R could be related to
structural changes in the brain.
Moreover, the association between obesity and MDD-R
could also be explained in terms of their onset (etiology)
and the triggering mechanisms [24,26]. The dynamic-
stress-vulnerability and kindling hypotheses state that new
episodes of major depression, i.e. MDD-S, are triggered
by stressful life events, whereas MDD-R are triggered
relatively more by stable risk factors [24,25]. Essentially,
multiple episodes indicate that the brain has become
desensitized to further stressful events [24], and stable
factors like obesity could contribute to the development
of recurrent depression.
In contrast, we did not observe an association of either
MDD-S or MDD-R with the development of obesity.
However, lifetime diagnosis of MDD tended to be associ-
ated with the subsequent development of obesity during
follow-up, though without statistical significance. To our
knowledge, only two studies revealed significant associa-
tions between depression and subsequent development
of obesity [16,20]. Both of these studies showed the bi-
directional associations between obesity and depression
[20]. However, the significant associations between de-
pression and development of obesity could be due to
the use of anti-depressant drugs or the higher power of
the studies [20,22,41]. Zimmermann et al. found that
long-term treatment with most antidepressant medica-
tions results in significant weight gain among depressed
patients [42]. In a large, nested case–control study with
4-year follow-up, the users of different types of anti-
depressant medication gained significantly more weight
than non-users [43,44].
Strengths and limitations
A major strength of our study was that we assessed
major depressive disorder using the CIDI, whereas most
studies so far relied on self-reported questionnaires.
Furthermore, we were able to discriminate between sin-
gle major depressive disorder (MDD-S) and recurrent
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separate contributions in relation to obesity. In addition,
using lifetime depression as the time frame for major
depression assessment in the present study provided the
opportunity to consider a cumulative effect of major de-
pression on obesity. The prevalence of obesity in our
study (16.9%) was lower than that in the US, but slightly
higher than that reported earlier for the Netherlands
(10-12%) [41], and within the range of the WHO European
region prevalence (10-30%) [1]. Our findings are likely
to be generalizable to most European countries, but the
findings should be replicated in countries with a higher
prevalence rate of obesity such as the US.
The main limitation of the study was that data on the
use of antidepressants was not available and we were
therefore not able to analyse the potential confounding
effect of this variable on the onset of obesity. Further
studies are needed to assess the potential role of these
factors. Moreover, when depressed persons were ex-
cluded, we did not find a statistically significant differ-
ence between included and excluded persons regarding
BMI. Also for lifetime prevalences of MDD, we did not
find a statistically significant difference when obese per-
sons were excluded.
Implications of the study
Our findings may have major public health importance
and add to the available evidence that obesity may be
specifically associated with the onset of multiple episodes
of major depression (MDD-R). For clinical practice, obese
patients deserve particular attention because obesity
is associated with new onset of MDD-R. Accordingly,
monitoring depressive symptoms in obese individuals
is important. This finding strongly supports a subtyp-
ing of the heterogeneous depression diagnosis of
depression in future research. As weight reduction in
depressed patients is evidently hard to reach, there is
also a need for further studies examining whether
weight loss interventions are effective in reducing the
recurrence of major depression.
Conclusions
This prospective study provides suggestive evidence that
obesity is associated with the subsequent onset of
MDD-R but not of MDD-S among adults in the general
population. Although the reverse association was not
found, MDD-R tends to be also associated with subse-
quent development of obesity, but larger studies are
needed to fully assess this issue. The heterogeneity of
MDD should be considered when examining the effect
of obesity on MDD.
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